Monitoring Patients with Parkinson’s Disease Using Gamma-glutamyl cysteine Supplementation

STUDY BASICS

Have you recently been diagnosed with Parkinson’s Disease? You may be eligible for a research study investigating how the antioxidant, gamma-glutamylcysteine (GGC), affects brain health, motor function, oxidative stress and cognitive function. Participation includes MRI scans, cognitive testing, and blood and stool analysis to assess changes over time. Compensation is provided.

STUDY PURPOSE

This research study will investigate whether oral supplementation with gamma-glutamyl cysteine (GGC; commercially available as Continual-G) changes the brain and blood glutathione (GSH) levels in patients with Parkinson’s Disease (PD).  Glutathione is a master antioxidant produced by the body through a natural process that helps repair cells, reduces oxidative stress, and inflammation.  This pilot trial aims to determine whether increasing brain GSH through GGC supplementation can alleviate symptoms or slow progression in PD.

COULD THIS STUDY BE RIGHT FOR YOU?

• Recently diagnosed with Parkinson’s Disease
• Motor symptoms
• No recent head injury
• 50-80 years old

WHAT PARTICIPANTS CAN EXPECT

• 12 month commitment of GGC 2 times a day
• Two in person visits to UPMC Presbyterian
• Provide blood and stool samples at each visit
• Complete neuropsychological tests at baseline and the 12 month follow-up